{{POV|date=September 2014}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462094956
| IUPAC_name = (2''S'')-6-<nowiki>[[[</nowiki>(''Z'')-[(4''S'',4a''S'',5a''S'',6''S'',12a''S'') -4-(Dimethylamino)-6,10,11,12a-tetrahydroxy-6-methyl-1,3,12-trioxo-4,4a,5,5a-tetrahydrotetracen-2-ylidene]-hydroxymethyl]amino]methylamino]-2-aminohexanoic acid
| image = Lymecycline.svg
| width = 300

<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|international|lymecycline}}
| pregnancy_category =
| legal_status =
| legal_AU = Schedule 4
| routes_of_administration = [[Oral administration|By mouth]]

<!--Pharmacokinetic data-->
| bioavailability = 100% (oral)
| metabolism =
| elimination_half-life = 10 hours
| excretion = [[Kidney]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 992-21-2
| ATC_prefix = J01
| ATC_suffix = AA04
| PubChem = 54707177
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00256
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 20121315
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7D6EM3S13P
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06884

<!--Chemical data-->
| C=29 | H=38 | N=4 | O=10 
| molecular_weight = 602.63
| smiles = C[C@@]1([C@H]2C[C@H]3[C@@H](C(=C(C(=O)[C@]3(C(=C2C(=O)C4=C1C=CC=C4O)O)O)C(=O)NCNCCCC[C@@H](C(=O)O)N)O)N(C)C)O
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C29H38N4O10/c1-28(42)13-7-6-9-17(34)18(13)22(35)19-14(28)11-15-21(33(2)3)23(36)20(25(38)29(15,43)24(19)37)26(39)32-12-31-10-5-4-8-16(30)27(40)41/h6-7,9,14-16,21,31,34,36-37,42-43H,4-5,8,10-12,30H2,1-3H3,(H,32,39)(H,40,41)/t14-,15-,16-,21-,28+,29-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = AHEVKYYGXVEWNO-UEPZRUIBSA-N
}}

'''Lymecycline''' is a [[tetracycline antibiotics|tetracycline]] [[broad-spectrum antibiotic]] marketed by the pharmaceutical company [[Galderma]]. It is approximately 5,000 times more [[soluble]] than [[tetracycline]] base and is unique amongst tetracyclines in that it is [[Absorption (chemistry)|absorbed]] by an [[active transport]] process across the intestinal wall, making use of the same  fast and efficient mechanism by which [[carbohydrate]]s are absorbed.<ref>[[New Zealand]] [http://www.medsafe.govt.nz/profs/Datasheet/t/Tetralysalcap.htm Datasheet] August 2003</ref>

The greater absorption of lymecycline allows for lower dosages to be used; the standard dose of 408&nbsp;mg is equivalent to 300&nbsp;mg tetracycline base and, in its action, to 500&nbsp;mg tetracycline hydrochloride. Lymecycline, unlike tetracycline hydrochloride, is soluble at all [[physiological]] [[pH]] values.

==History==
Lymecycline was released into the pharmaceutical market in 1963.

==Indications==
Lymecycline, like other tetracyclines, is used to treat a range of infections.  Its better absorption profile makes it preferable to tetracycline for moderately severe [[Acne vulgaris|acne]] and typically prescribed for 8 weeks at a time, but alternatives should be sought if no improvement occurs by 3 months.<ref>[[British National Formulary]] ''45'' March 2003</ref>

[[File:Tetralysal tablets with packaging in background.jpg|thumb|250px|Lymecycline capsules]]

== Side effects ==
Lymecycline's side effects can include [[rash]], [[headache]], [[Diarrhea|diarrhoea]], [[ulcerative colitis]], [[nausea]], [[vomiting]], [[dermatitis]], [[Aphasia|dysphasia]], inflammation of the liver, [[Hypersensitive response|hypersensitive reactions]], and [[Vision disorder|visual disturbances]]. When taken for a long period of time, it can cause [[reflux oesophagitis]].<ref>{{cite web|last=Dr Wang|first=Peter|title=Side effects of Tetralysal|url=http://www.steadyhealth.com/about/side_effects_of_tetralysal.html|accessdate=23 March 2011}}</ref>


==References==
{{Reflist}}

==See also==
* [[Timeline of antibiotics]]

{{TetracyclineAntiBiotics}}

[[Category:Amino acid derivatives]]
[[Category:Anti-acne preparations]]
[[Category:Tetracycline antibiotics]]